SR One Capital Management, LP
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 13, 2024), SR One Capital Management, LP reported 6 stock positions worth $364.1 million. Its top holding was Arcellx (ACLX) at 44.8% of the portfolio, followed by Crispr Therapeutics (CRSP, 19.6%) and Ars Pharmaceuticals (SPRY, 11.3%). Compared with Q4 2023, it opened 1 new position, added to 2 and reduced 1. The biggest buy was a new position in Crispr Therapeutics (CRSP) and the biggest sale Arcellx (ACLX, shares −25%).
- Most Recent 13F
- Q2 2026
- Location
- Redwood City, CA
- CIK
- 0001910264
- Portfolio Value
- $364.1M (Q1 2024)
- SEC Filing
- 0001910264-24-000003 ↗ filed May 13, 2024
Holdings Value
Holdings 6 stocks · $364.1M
| ACLX Arcellx Inc. | 44.83% | 2,346,630 | $163.2M | Reduce -25.4% |
| CRSP Crispr Therapeutics AG | 19.64% | 1,048,951 | $71.5M | New |
| SPRY Ars Pharmaceuticals Inc. | 11.26% | 4,012,903 | $41.0M | No change |
| NKTX Nkarta Inc. | 9.90% | 3,333,333 | $36.0M | Add +150.0% |
| DSGN Design Therapeutics Inc. | 7.22% | 6,526,476 | $26.3M | No change |
| MLYS Mineralys Therapeutics Inc. | 7.15% | 2,016,822 | $26.0M | Add +12.4% |
Portfolio Sells Q4 2023 → Q1 2024
| ACLX Arcellx Inc. | Reduce -25.4% | 44.83% | −28.50 |
Portfolio Buys Q4 2023 → Q1 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 15 | $1.0B | MANE, ZBIO, CRSP, AVLN, DSGN |
| Q1 2026 | 14 | $915.4M | ACLX, MANE, ZBIO, CRSP, DSGN |
| Q4 2025 | 13 | $706.4M | ZBIO, ACLX, CRSP, DSGN, MLYS |
| Q3 2025 | 12 | $691.4M | ACLX, CRSP, ZBIO, MLYS, ORIC |
| Q2 2025 | 13 | $461.4M | ACLX, SPRY, CRSP, ZBIO, ORIC |
| Q1 2025 | 12 | $389.3M | ACLX, SPRY, MLYS, ZBIO, CRSP |
| Q4 2024 | 11 | $410.1M | ACLX, SPRY, CRSP, DSGN, ZBIO |
| Q3 2024 | 11 | $498.7M | ACLX, ZBIO, SPRY, CRSP, DSGN |
| Q2 2024 | 9 | $319.4M | ACLX, CRSP, SPRY, ALMS, MLYS |
| Q1 2024 | 6 | $364.1M | ACLX, CRSP, SPRY, NKTX, DSGN |